Tiziana Life Sciences Ltd
NASDAQ:TLSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tiziana Life Sciences Ltd
NASDAQ:TLSA
|
UK |
|
A
|
Amtd International Inc
NYSE:AMTD
|
HK |
|
R
|
Rigolleau SA
BCBA:RIGO
|
AR |
|
F
|
Fubon No.2 Real Estate Investment Trust
TWSE:01004T
|
TW |
|
G
|
Guardian Capital Group Ltd
OTC:GCAAF
|
CA |
|
Live Company Group PLC
LSE:LVCG
|
UK |
|
B
|
Berjaya Assets Bhd
KLSE:BJASSET
|
MY |
|
L
|
London City Equities Ltd
ASX:LCE
|
AU |
|
S
|
SMCG Co Ltd
KOSDAQ:460870
|
KR |
|
C
|
Centrum Medyczne Enel Med SA
WSE:ENE
|
PL |
|
Skanska AB
STO:SKA B
|
SE |
|
P
|
Pricer AB
STO:PRIC B
|
SE |
|
European Medical Solutions
XBRU:ALEMS
|
BE |
Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. The firm is focused on the discovery and development of molecules and related diagnostics to treat unmet medical needs in oncology and immunology. Its lead product candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501), and Milciclib TZLS-201. Foralumab (TZLS-401) is a fully human engineered anti-human cluster of differentiation 3 (CD3) monoclonal antibody (mAb). Foralumab is developed for the treatment of neurodegenerative diseases such as progressive Multiple Sclerosis (MS), and Crohn’s disease. The Anti IL-6R mAb (TZLS-501) is a fully human engineered mAb targeting the interleukin-6 receptor (IL-6R). Anti-IL-6R antibody can be used in combination with Foralumab or other anti-inflammatory and anti-infective agents as therapy for COVID-19 and oncology indications. The firm has developed Milciclib TZLS-201 for the treatment of hepatocellular carcinoma (HCC).
Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. The firm is focused on the discovery and development of molecules and related diagnostics to treat unmet medical needs in oncology and immunology. Its lead product candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501), and Milciclib TZLS-201. Foralumab (TZLS-401) is a fully human engineered anti-human cluster of differentiation 3 (CD3) monoclonal antibody (mAb). Foralumab is developed for the treatment of neurodegenerative diseases such as progressive Multiple Sclerosis (MS), and Crohn’s disease. The Anti IL-6R mAb (TZLS-501) is a fully human engineered mAb targeting the interleukin-6 receptor (IL-6R). Anti-IL-6R antibody can be used in combination with Foralumab or other anti-inflammatory and anti-infective agents as therapy for COVID-19 and oncology indications. The firm has developed Milciclib TZLS-201 for the treatment of hepatocellular carcinoma (HCC).
